Peripheral Artery Disease (PAD)

This channel includes news, interventions, and new technology innovations for peripheral artery diease, PAD and critical limb ischemia.

COMPASS open label extension study results support the long-term use of XARELTO plus aspirin for vascular protection in patients with chronic CAD and/or PAD

News | Cardiovascular Clinical Studies

New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition with XARELTO Plus Aspirin in Patients with Coronary Artery Disease, Peripheral Artery Disease

May 31, 2022 — Findings from the XARELTO (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and ...

May 31, 2022

Three years ago a study raised concerns that paclitaxel-coated devices may cause increased mortality in peripheral artery disease patients. However, numerous studies now show there is no risk of increased mortality. The most recent study is the SAFE-PAD study presented at SCAI22.

News | Peripheral Artery Disease (PAD)

New Longterm Data of Paclitaxel Devices Continues to Show No Increased Mortality Compared to Non-drug Coated Devices

May 20, 2022 — New long-term data from the Safety Assessment of Femoropopliteal Endovascular Treatment With PAclitaxel ...

May 20, 2022

First multi-center, randomized controlled study provides the largest long-term evidence for the treatment of heavily calcified femoropopliteal lesions

News | Peripheral Artery Disease (PAD)

Disrupt PAD III Trial Demonstrates Safety and Effectiveness of Intravascular Lithotripsy for Peripheral Artery Calcification

May 19, 2022 — One year outcomes from the Disrupt PAD III Trial comparing intravascular lithotripsy (IVL) with a drug ...

May 19, 2022

Transit Scientific announced the FDA clearance of its XO Cross Support Catheter Platform to include coronary use.

News | Guidewires

FDA Clears Four New Coronary Micro Support Catheters

April 12, 2022 — Transit Scientific announced the FDA clearance of its XO Cross Support Catheter Platform to include ...

April 12, 2022

With 60 years of experience, The Cardiovascular Care Group is nationally recognized for vascular and endovascular care. In addition to providing quality care to tens of thousands of patients over the years, The Cardiovascular Care Group has been committed to educating the community on vascular-related conditions through the sharing of knowledge and transparency.

News | Peripheral Artery Disease (PAD)

The Cardiovascular Care Group Raises Awareness of Peripheral Artery Disease

March 22, 2022 – With 60 years of experience, The Cardiovascular Care Group is nationally recognized for vascular ...

March 22, 2022

Medtronic is recalling (correcting) the TurboHawk Plus Directional Atherectomy System due to design similarities shared with another device that was recently recalled for correction.

News | Atherectomy Devices

Class I Recall on TurboHawk Plus Directional Atherectomy System by Medtronic

March 9, 2022 — Medtronic is recalling (correcting) the TurboHawk Plus Directional Atherectomy System due to design ...

March 09, 2022

Angioscopic findings in the FPA and infrapopliteal lesions

News | Peripheral Artery Disease (PAD)

Study Finds Ulcerated Plaque in the Femoropopliteal Artery as Source of Arterial Embolism in the Popliteal Arteries

February 21, 2022 – A research group the Department of Cardiovascular Medicine, Osaka City University Graduate School of ...

February 21, 2022

News | Peripheral Artery Disease (PAD)

Alkem Licenses Technology from Harvard University, Aiming to Treat Ischemic Injury and Vascular Diseases

February 15, 2022 – Alkem Laboratories Limited (Alkem), an Indian multinational pharmaceutical company, has signed a ...

February 15, 2022

Medtronic Inc. is recalling its HawkOne Directional Atherectomy System product due to the risk of the guidewire within the catheter moving downward or prolapsing when force is applied during use.

News | Atherectomy Devices

Medtronic Recalls HawkOne Atherectomy System Due to Risk of Tip Damage During Use

January, 24, 2022 — Medtronic Inc. is recalling its HawkOne Directional Atherectomy System product due to the risk of ...

January 24, 2022

The Endologix PQ Bypass System is a percutaneous femoral-popliteal bypass system that enables a minimally invasive, catheter-based procedure to put a graft in a patient's femoral vein to bypass blockages in the SFA.

News | Peripheral Artery Disease (PAD)

First-of-its-Kind Outpatient Transcatheter Leg Artery Bypass Procedure Performed

January 17, 2022 – The Vascular Care Group (TVCG) announced Stephen J. Hoenig M.D., successfully completed a ...

January 17, 2022

An Abbott Vascular survey found one in four physicians surveyed feel lack of technology makes an accurate diagnosis of coronary artery disease and peripheral artery disease a key obstacle to an accurate diagnosis. Getty Images

News | Cardiac Diagnostics

Research Finds Challenges in Vascular Disease Symptom Recognition and Diagnostic Testing Impacts Patient Satisfaction

November 10, 2021 — Abbott released new global market research from its Beyond Intervention initiative, the company’s ...

November 10, 2021

A new large-scale, real-world analysis of Centers for Medicare and Medicaid Services (CMS) outcomes data from of peripheral vascular interventions guided by intravascular ultrasound (IVUS) showed a 32% reduction in major adverse limb events, such as amputations, during lower extremity arterial intervention.

News | Intra-Vascular Ultrasound (IVUS)

IVUS Improved Outcomes in Largest Real-world Analysis of Lower Extremity Peripheral Vascular Interventions

November 9 2021 — A new large-scale, real-world analysis of Centers for Medicare and Medicaid Services (CMS) outcomes ...

November 09, 2021

Philips, a global leader in health technology and IVUS solutions, announced that a worldwide committee of 40 cross-specialty medical experts achieved the first-ever consensus for the appropriate use of intravascular ultrasound (IVUS) in peripheral vascular disease (PVD) interventions

News | Intra-Vascular Ultrasound (IVUS)

First-ever Global Consensus for the Appropriate Use of IVUS in Peripheral Vascular Disease Interventions

October 20, 2021 — Philips, a global leader in health technology and intravascular ultrasound (IVUS) solutions ...

October 20, 2021

The objective of this clinical investigation has been to evaluate safety and performance outcomes of SELUTION SLR, MedAlliance’s novel sirolimus-eluting balloon, for the treatment of long tibial occlusive lesions (TASC C & D) in patients with Critical Limb Ischemia (CLI). It was presented at VIVA 2021.

News | Drug-Eluting Balloons

18-Month Below-the-Knee Data With MedAlliance’s SELUTION SLR Presented at VIVA

October 20, 2021 — 18-month results from the PRESTIGE* Below-the-Knee (BTK) study have been presented as a late-breaking ...

October 20, 2021

the Eluvia stent exhibited superiority with a primary patency rate of 85.4% versus 76.3% with BMS (p=0.0077).1 The analysis also confirmed a significantly greater rate of sustained clinical improvement without reintervention

News | Peripheral Artery Disease (PAD)

Boston Scientific Eluvia Drug-Eluting Vascular Stent System Exhibits Superiority Compared to Bare Metal Stents

October 20, 2021 — Boston Scientific Corporation announced positive data for the Eluvia Drug-Eluting Vascular Stent ...

October 20, 2021